For Patients

For Patients

Immunovant is currently investigating therapies for people with myasthenia gravis (MG), thyroid eye disease (TED), and warm autoimmune hemolytic anemia (WAIHA).

Subcutaneous Delivery

We intend to develop IMVT-1401 as a fixed-dose subcutaneous injection to be administered at home.

Ongoing Trials

Summary information about our ongoing trials is provided below. For more information, please visit www.clinicaltrials.gov

A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

Brief Summary: The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in MG patients following treatment with RVT-1401 (currently known as IMVT-1401) compared to placebo.

Estimated Enrollment: 21 participants
Study Start Date: May 21, 2019
clinicaltrials.gov

A Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Thyroid Eye Disease (TED)

Brief Summary: The purpose of the current study is to confirm safety/tolerability and key pharmacodynamic (PD) effects that are considered to drive clinical benefit in TED patients.

Estimated Enrollment: 8 participants
Study Start Date: April 22, 2019
clinicaltrials.gov

A Study of RVT-1401 for the Treatment of Patients with Active, Moderate to Severe Thyroid Eye Disease (TED)

Brief Summary: The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 (currently known as IMVT-1401) in the treatment of active, moderate to severe TED patients. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG.

Estimated Enrollment: 77 participants
Study Start Date: July 23, 2019
clinicaltrials.gov

An Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia (WAIHA)

Brief Summary: The purpose of the current study is to assess the efficacy and safety/tolerability of two dose regimens of RVT-1401 (currently known as IMVT-1401) in the treatment of patients who have failed or not tolerated at least one prior treatment for WAIHA. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in IgG and other exploratory biomarkers.

Estimated Enrollment: 16 participants
Study Start Date: July 2020
clinicaltrials.gov

Contact Info

If you would like to learn more about our clinical trials, please contact clinicaltrials@immunovant.com